pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›AFREZZA
drug · protein
save

AFREZZA

updated 3mo ago
by $MNKD MANNKIND CORP🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval56 co-mentions · 14 sources
  • druginsulin human28 co-mentions · 14 sources
  • druginsulin human (recombinant)28 co-mentions · 14 sources
  • drugAT-27828 co-mentions · 14 sources
  • druginsulin28 co-mentions · 14 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for diabetes mellitus and type 2 diabetes mellitus and 46 investigational indications.

targets

Insulin receptor

all catalysts(0)

nothing on the calendar yet

Trials studying AFREZZA

  • phase3Afrezza® INHALE-1 Study in Pediatricscompletedn=319
  • phase4Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetescompletedn=33
  • phase4INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetescompletedn=141
  • phase3Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patientscompletedn=20
  • phase4Afrezza® Dosing Optimization Studycompletedn=20

News(0)

no news has mentioned this drug yet

brand
AFREZZA
trade names
Actrapid, Afrezza, Exubera, Humulin br, Humulin r, Inpremzia
generic
INSULIN RECOMBINANT HUMAN
MOA
12.1 Mechanism of Action Insulin lowers blood glucose levels in adult patients with diabetes mellitus by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.
indication
1 INDICATIONS AND USAGE AFREZZA ® is indicated to improve glycemic control in adult patients with diabetes mellitus. AFREZZA ® is a rapid acting inhaled human insulin indicated to improve glycemic control in adult patients with diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for the treatment of diabetic ketoacidosis (DKA) ( 1 ) Not recommended in patients who smoke or who have recently stopped smoking ( 1 ) Limitations of Use: AFREZZA is not recommended for the treatment of diabetic ketoacidosis (DKA) [see Warning and Precautions ( 5.6 )] . The safety and effectiveness of AFREZZA in patients who smoke have not been established. The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking.
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 34m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?